The Incidence of Adverse Events in Patients Treated with Therapeutic Dose Enoxaparin in Relation to Body Mass Index

Mustafa Murtadha, Riyadh

	The Incidence of Adverse Events in Patients Treated with Therapeutic Dose Enoxaparin in Relation to Body Mass Index
Kerbala Journal of Medicine
Article 4, Volume 10, Issue 3, 2017, Pages 3827-3832 PDF (0 K)
Author
Riyadh Mustafa Murtadha
Abstract
background: Low Molecular Weight Heparin (LMWH) has widely replaced its parent and oldest anticoagulant compound “Heparin” due to its numerous advantages. However, LMWH are not devoid of adverse effects which may be serious. Since the therapeutic dose of LMWH “Enoxaparin” is determined by a weight-based regimen, the incidence of adverse events may be increased when using higher doses in overweight & obese patients. Aim: to assess the incidence of adverse events in acutely thrombosed patients treated with therapeutic dose Enoxaparin in relation to Body Mass Index (BMI). Methods: A prospective study conducted through a 6 months period in 2014 including 181 patients (98 males, 83 females) with acute thrombotic disorders admitted to the cardiac care unit in Al-Hussein Medical city in Karbala-Iraq. All patients who had normal renal functions, were received weight-based LMWH in the form of Enoxaparin. They were subdivided according to their BMI into 3 groups; normal, overweight and obese. Any evidence of adverse events were followed and recorded. Results: Bleeding was the most common adverse event occur in 15 out of 181 patients (8.3%), categorized as Major bleeding comprising 2.2% overall, occur in 2% of normal BMI, 1.6% of overweight, & 2.9% of obese patients, and Minor bleeding comprising 6.1% overall, occur in 5.9% of normal BMI, 6.5% of overweight, & 5.8% of obese patients. No death was reported related to bleeding. Other adverse events were thrombocytopenia in 2.6%, and fever in 1.1% overall. There was no statistically significant difference regarding all adverse events among the 3 groups. Conclusion: The incidence of bleeding and other adverse events was not found to be increased in relation to BMI when using weight-based therapeutic dose Enoxaparin, which may indicate the rationale use of this regimen in patients with acute thrombotic disorders.
Keywords
Low Molecular Weight Heparin; Enoxaparin; Body mass Index

Statistics Article View: 175 PDF Download: 107